New study tracks gene mutations in indian breast cancer patients
NCT ID NCT05022342
First seen Jan 02, 2026 · Last updated May 24, 2026 · Updated 21 times
Summary
This study looked at 595 people in India with a certain type of advanced breast cancer (HR-positive, HER2-negative). Researchers checked for changes in the PIK3CA gene and tracked how patients did on the drug alpelisib. No new treatments were given—doctors made all decisions as usual. The goal was to learn more about the disease and treatment outcomes in this population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Hyderabad, Andhra Pradesh, 500034, India
-
Novartis Investigative Site
Guwahati, Assam, 781023, India
-
Novartis Investigative Site
Kochi, Kerala, 682041, India
-
Novartis Investigative Site
Bhopal, Madhya Pradesh, 462001, India
-
Novartis Investigative Site
Mumbai, Maharashtra, 400 012, India
-
Novartis Investigative Site
Mumbai, Maharashtra, 400071, India
-
Novartis Investigative Site
Nagpur, Maharashtra, 440001, India
-
Novartis Investigative Site
Nagpur, Maharashtra, 441108, India
-
Novartis Investigative Site
Pune, Maharashtra, 411004, India
-
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110060, India
-
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110092, India
-
Novartis Investigative Site
Bhubaneswar, Odisha, 751003, India
-
Novartis Investigative Site
Bhubaneswar, Odisha, 751007, India
-
Novartis Investigative Site
Chandigarh, Punjab, 160055, India
-
Novartis Investigative Site
Ludhiana, Punjab, 141008, India
-
Novartis Investigative Site
Jaipur, Rajasthan, 302017, India
-
Novartis Investigative Site
Sherilingampally, Telangana, 500019, India
-
Novartis Investigative Site
Howrah, West Bengal, 711103, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700029, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700054, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700063, India
-
Novartis Investigative Site
Ahmedabad, 380054, India
-
Novartis Investigative Site
Kanpur, 208002, India
-
Novartis Investigative Site
Kolkata, 700016, India
-
Novartis Investigative Site
Kolkata, 700026, India
-
Novartis Investigative Site
Kolkata, 700107, India
-
Novartis Investigative Site
Puducherry, 605006, India
-
Novartis Investigative Site
Udaipur, 313011, India
Conditions
Explore the condition pages connected to this study.